Characteristics of patients (n = 71)
| . | AP-CE (n = 15) . | HEM-AP (n = 32) . | HEM-AP + CE (n = 24) . |
|---|---|---|---|
| Sex, M/F | 11, 4 | 16, 16 | 16, 8 |
| Mean age, y (range) | 56 (38-76) | 60 (27-75) | 57 (22-74) |
| Mean CML duration, mo (range) | 45 (6-120) | 47 (6-108) | 58 (9-168) |
| Mean Hb, g/dL (range) | 12.1 (9.2-15.8) | 10.1 (2.7-15.4) | 10.3 (7.3-15.4) |
| Mean white blood cell count, × 109/L (range) | 15 (1.8-70.8) | 38.2 (2.5-173.9) | 48.5 (1.8-163) |
| Mean blasts, % (range) | 2.48 (0-7) | 12.8 (0-26) | 14 (1-25) |
| Mean basophils, % (range) | 4.1 (0-11) | 14.6 (0-76) | 13 (0-47) |
| Mean platelets, × 109/L (range) | 341 (129-826) | 512 (34-2252) | 342 (10-1018) |
| Mean duration prior interferon therapy, mo (range) | 17 (1-83) | 13 (1-79) | 25 (5-12) |
| Prior chemotherapy, no. | 7 | 13 | 9 |
| Prior stem cell transplant, no. | 3 autologous 4 allogeneic | 2 autologous | 3 autologous 2 allogeneic |
| Spleen larger than 10 cm, no. | 0 | 13 | 11 |
| Additional Ph, no. (%) | 3 (20) | — | 5 (21) |
| Chromosome 17 abnormalities, no. (%) | 3 (20) | — | 8 (33) |
| Other translocations, no. (%) | 4 (27) | — | 9 (37.5) |
| Mean metaphases with additional abnormalities, % (median) | 56 (50) | — | 63 (77) |
| . | AP-CE (n = 15) . | HEM-AP (n = 32) . | HEM-AP + CE (n = 24) . |
|---|---|---|---|
| Sex, M/F | 11, 4 | 16, 16 | 16, 8 |
| Mean age, y (range) | 56 (38-76) | 60 (27-75) | 57 (22-74) |
| Mean CML duration, mo (range) | 45 (6-120) | 47 (6-108) | 58 (9-168) |
| Mean Hb, g/dL (range) | 12.1 (9.2-15.8) | 10.1 (2.7-15.4) | 10.3 (7.3-15.4) |
| Mean white blood cell count, × 109/L (range) | 15 (1.8-70.8) | 38.2 (2.5-173.9) | 48.5 (1.8-163) |
| Mean blasts, % (range) | 2.48 (0-7) | 12.8 (0-26) | 14 (1-25) |
| Mean basophils, % (range) | 4.1 (0-11) | 14.6 (0-76) | 13 (0-47) |
| Mean platelets, × 109/L (range) | 341 (129-826) | 512 (34-2252) | 342 (10-1018) |
| Mean duration prior interferon therapy, mo (range) | 17 (1-83) | 13 (1-79) | 25 (5-12) |
| Prior chemotherapy, no. | 7 | 13 | 9 |
| Prior stem cell transplant, no. | 3 autologous 4 allogeneic | 2 autologous | 3 autologous 2 allogeneic |
| Spleen larger than 10 cm, no. | 0 | 13 | 11 |
| Additional Ph, no. (%) | 3 (20) | — | 5 (21) |
| Chromosome 17 abnormalities, no. (%) | 3 (20) | — | 8 (33) |
| Other translocations, no. (%) | 4 (27) | — | 9 (37.5) |
| Mean metaphases with additional abnormalities, % (median) | 56 (50) | — | 63 (77) |